IMM vs. VRP, FARN, ARIX, CIR, BVXP, 4BB, TILS, VSN, SCLP, and MPH
Should you be buying ImmuPharma stock or one of its competitors? The main competitors of ImmuPharma include Verona Pharma plc (VRP.L) (VRP), Faron Pharmaceuticals Oy (FARN), Arix Bioscience (ARIX), Circassia Group (CIR), Bioventix (BVXP), 4basebio (4BB), Tiziana Life Sciences (TILS), Verseon (VSN), Scancell (SCLP), and Mereo BioPharma Group plc (MPH.L) (MPH). These companies are all part of the "biotechnology" industry.
ImmuPharma vs. Its Competitors
Verona Pharma plc (VRP.L) (LON:VRP) and ImmuPharma (LON:IMM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.
ImmuPharma has a net margin of 3,519.56% compared to Verona Pharma plc (VRP.L)'s net margin of 0.00%. Verona Pharma plc (VRP.L)'s return on equity of 0.00% beat ImmuPharma's return on equity.
6.1% of ImmuPharma shares are owned by institutional investors. 8.1% of ImmuPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
ImmuPharma is trading at a lower price-to-earnings ratio than Verona Pharma plc (VRP.L), indicating that it is currently the more affordable of the two stocks.
In the previous week, ImmuPharma had 22 more articles in the media than Verona Pharma plc (VRP.L). MarketBeat recorded 22 mentions for ImmuPharma and 0 mentions for Verona Pharma plc (VRP.L). ImmuPharma's average media sentiment score of 0.28 beat Verona Pharma plc (VRP.L)'s score of 0.00 indicating that ImmuPharma is being referred to more favorably in the news media.
Summary
ImmuPharma beats Verona Pharma plc (VRP.L) on 6 of the 9 factors compared between the two stocks.
Get ImmuPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IMM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuPharma Competitors List
Related Companies and Tools
This page (LON:IMM) was last updated on 10/23/2025 by MarketBeat.com Staff
